Regeneron Study Combines Cancer Drug and Antibody to Train Immune Memory
A study by Regeneron researchers published in Nature Communications shows that combining an existing cancer drug with an experimental antibody eliminates tumors in mice and trains the immune system to prevent recurrence.

A recent study published in the scientific journal Nature Communications reveals a promising dual-action cancer therapy that not only eliminates existing tumors in mice but also trains the immune system to prevent recurrence without additional drugs. Researchers from the US biotechnology company Regeneron combined an existing targeted medication with an experimental antibody, achieving complete tumor remission and long-term immune memory against cancer.
Dual-Action Treatment Approach
The human immune system retains a lasting memory of past pathogens such as viruses and bacteria, allowing it to mount a swift and effective defense upon re-exposure. Scientists aimed to harness this same biological mechanism to combat cancer, programming the body to recognize and destroy malignant cells if they reappear. The research utilized Enhertu, an approved drug currently prescribed for specific types of breast, stomach, and other cancers, which attaches to a specific protein on cancer cells to deliver a localized payload.
To boost efficacy, the team paired Enhertu with an experimental antibody designed to stimulate immune cells and orchestrate an active assault against the tumor. In initial trials involving mice with breast cancer models, administering the standard drug alone eradicated tumors in fewer than half of the subjects, even at the highest tested doses. However, combining the medication with the experimental antibody yielded a 100 percent success rate, completely eliminating tumors in all nine test subjects.
Immune System Memory and T-Cell Activation
To determine whether the protective effect persisted after treatment concluded, researchers waited at least four weeks while the mice remained tumor-free, then reintroduced identical cancer cells without any further medication. The immune system successfully blocked the newly introduced cells from forming tumors, demonstrating that the therapy established a sustained immunological response.
Additional experiments showed that this immune memory was highly specific. When researchers injected a different type of tumor cells expressing a shared protein, those cells successfully formed tumors. This indicated that the body developed targeted immunity against the specific malignant profile rather than broad, universal protection. Subsequent analysis confirmed that T-cells played an essential role, as depleting specific T-cell populations completely neutralized the therapy's effectiveness.
Broader Applications and Future Outlook
Beyond the initial breast cancer model, researchers tested the experimental antibodies in combination with other treatments. Pairing the antibody with Enhertu induced tumor regression in approximately 75 percent of mice carrying treatment-resistant tumors. Furthermore, combining the experimental antibody with the chemotherapy drug fluorouracil successfully slowed tumor growth in scenarios where individual treatments had negligible impact.
"The findings demonstrate that engaging the immune system alongside targeted therapies can create lasting defenses against cancer recurrence," the research team noted in their publication.
Despite the encouraging results in murine models, scientists emphasize that the methodology requires extensive clinical testing to establish safety and efficacy in humans. The experiments do not fully capture potential side effects, including impacts on the lungs, heart, gastrointestinal tract, and skin. One of the experimental antibodies evaluated in the study has already entered early-stage clinical trials in humans, while Regeneron has filed patent applications related to the findings.





